Profound Medical Corp. (PROF) stock

PROFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30

$7.44−0.41 (-5.22%)

Close on Nov 12, 2026Market cap $271.80MP/E –Yield –

Profound Medical price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Profound Medical's price to sales ratio was 15.0× on Nov 11, 2026, against 13.9× a year earlier. Over the last 5 years it ranged from 11.1× to 40.6×, with a median of 21.9×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	15.0×	−1.6
2025	Dec 31, 2025	16.6×	−5.7
2024	Dec 31, 2024	22.3×	−4.2
2023	Dec 29, 2023	26.5×	−6.0
2022	Dec 30, 2022	32.4×	+5.8
2021	Dec 31, 2021	26.6×	−31.8
2020	Dec 31, 2020	58.4×	–

Where these numbers come from

Parsed from the XBRL in Profound Medical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing